DrugPatentWatch Database Preview
MIRVASO Drug Profile
Which patents cover Mirvaso, and when can generic versions of Mirvaso launch?
Mirvaso is a drug marketed by Galderma Labs Lp and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and six patent family members in thirty countries.
The generic ingredient in MIRVASO is brimonidine tartrate. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
Summary for MIRVASO
| International Patents: | 106 |
| US Patents: | 11 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 100 |
| Clinical Trials: | 10 |
| Drug Prices: | Drug price information for MIRVASO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MIRVASO |
| DailyMed Link: | MIRVASO at DailyMed |
Pharmacology for MIRVASO
| Drug Class | alpha-Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha-Agonists |
Medical Subject Heading (MeSH) Categories for MIRVASO
Synonyms for MIRVASO
| (5-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine |
| (5-bromoquinoxalin-6-yl)-2-imidazolin-2-ylamine |
| [3H]-UK14304 |
| [3H]brimonidine |
| 5-brom-n-(4,5-dihydro-1h-imidazol-2-yl)chinoxalin-6-amin |
| 5-bromanyl-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine |
| 5-bromo-6-(2-imidazolidinylidenamino)quinoxaline |
| 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline |
| 5-Bromo-6-(2-imidazolin-2-ylamino)-quinoxaline |
| 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline |
| 5-bromo-6-(imidazolidinylideneamino)quinoxaline |
| 5-bromo-6-(imidazolin-2-ylamino)quinoxaline |
| 5-Bromo-N-(2-imidazolin-2-yl)-6-quinoxalinamine |
| 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine |
| 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine |
| 59803-98-4 |
| 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- |
| 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- (9CI) |
| 6-Quinoxalinamine,5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- |
| 6-Quinoxalinamine,5-dihydro-1H-imidazol-2-yl)- |
| 70359-46-5 (tartrate[1:1]) |
| 803B984 |
| A832477 |
| AC-162 |
| AC1L1DO5 |
| AC1Q24IC |
| AC1Q26LW |
| AGN 190342 |
| AGN-190342 |
| AJ-78420 |
| AK-35795 |
| AKOS005267239 |
| AN-6804 |
| ANW-59812 |
| ARONIS24406 |
| B4132 |
| BC215787 |
| BDBM34572 |
| BIDD:GT0649 |
| brimonidina |
| brimonidine |
| Brimonidine (bioerodible, extended release) |
| Brimonidine (INN) |
| Brimonidine [INN:BAN] |
| brimonidinum |
| BRN 0751629 |
| Bromoxidine |
| C-18323 |
| C07886 |
| C11H10BrN5 |
| CAS-59803-98-4 |
| CC-25204 |
| CCG-205290 |
| CHEBI:3175 |
| CHEMBL844 |
| cid_2435 |
| CJ-16916 |
| CPD000058355 |
| CS-2892 |
| CTK5B0525 |
| D03ACG |
| D07540 |
| D0AE3X |
| D0GD9D |
| DB00484 |
| DR001107 |
| DSSTox_CID_25221 |
| DSSTox_GSID_45221 |
| DSSTox_RID_80758 |
| DTXSID3045221 |
| E6GNX3HHTE |
| EN300-50880 |
| EU-0101216 |
| FT-0082636 |
| FT-0630717 |
| FT-0650586 |
| GS-3236 |
| GTPL520 |
| GTPL5386 |
| HE358175 |
| HMS3259P09 |
| HMS3263D14 |
| HMS3266O03 |
| HY-B0659 |
| IMED608142799 |
| KB-197165 |
| KS-00000F2V |
| KS-000048KL |
| L000615 |
| LK 14304-18 |
| Lopac-U-104 |
| Lopac0_001216 |
| LP01216 |
| LS-142950 |
| Lumify |
| MCULE-4542695850 |
| MFCD00153878 |
| MLS000069370 |
| MLS001076349 |
| MolPort-003-959-841 |
| MRF-0000657 |
| NC00638 |
| NCGC00016069-01 |
| NCGC00016069-02 |
| NCGC00016069-03 |
| NCGC00016069-04 |
| NCGC00016069-05 |
| NCGC00016069-06 |
| NCGC00016069-07 |
| NCGC00016069-08 |
| NCGC00016069-09 |
| NCGC00016069-10 |
| NCGC00016069-11 |
| NCGC00016069-12 |
| NCGC00016069-13 |
| NCGC00023468-02 |
| NCGC00023468-04 |
| NCGC00023468-05 |
| NCGC00023468-06 |
| NCGC00023468-07 |
| NCGC00261901-01 |
| NSC-318825 |
| NSC318825 |
| Opera_ID_612 |
| PDSP1_000640 |
| PDSP2_000635 |
| SAM002548958 |
| SBB080815 |
| SCHEMBL24670 |
| SMR000058355 |
| SR-01000000023 |
| SR-01000000023-2 |
| ST2406733 |
| T6531398 |
| TC-148557 |
| Tocris-0425 |
| Tox21_110299 |
| Tox21_110299_1 |
| Tox21_501216 |
| TRA0032007 |
| UK 14,304 |
| UK 14,304-18 |
| UK 14304 |
| UK 14304-18 |
| UK 14308 |
| UK-14,304-18 |
| UK-14,308 |
| UK-14304 |
| UK14,304 |
| UK14304 |
| UNII-E6GNX3HHTE |
| XYLJNLCSTIOKRM-UHFFFAOYSA-N |
| Z802671510 |
| ZINC21303210 |
| ZX-AS004769 |
US Patents and Regulatory Information for MIRVASO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for MIRVASO
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Topical Gel | 0.33% | ➤ Subscribe | ➤ Sign Up |
International Patents for MIRVASO
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Portugal | 1761266 | ➤ Sign Up |
| San Marino | T201400156 | ➤ Sign Up |
| Hungary | E033143 | ➤ Sign Up |
| Japan | 2013523611 | ➤ Sign Up |
| Australia | 2011231543 | ➤ Sign Up |
| Spain | 2498217 | ➤ Sign Up |
| South Korea | 20130002338 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for MIRVASO
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 14/041 | Ireland | ➤ Sign Up | PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221 |
| C0056 | France | ➤ Sign Up | PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| 90049-2 | Sweden | ➤ Sign Up | PRODUCT NAME: BRIMONIDIN OCH FARMACEUTISKA SALTER DAERAV; REG. NO/DATE: EU/1/13/904 20140221 |
| 2014000080 | Germany | ➤ Sign Up | PRODUCT NAME: BRIMONIDIN UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON; REGISTRATION NO/DATE: EU/1/13/904 20140221 |
| 462 | Luxembourg | ➤ Sign Up | PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225 |
| 00683 | Netherlands | ➤ Sign Up | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| 1 5019-2014 | Slovakia | ➤ Sign Up | PRODUCT NAME: BRIMONIDIN; REGISTRATION NO/DATE: EU/1/13/904/001 - EU/1/13/904/003 20140221 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
